2013 Fiscal Year Final Research Report
Significance of chymase inhibition to prevent the complication of metabolic syndrome
| Project/Area Number |
23590313
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
TAKAI Shinji 大阪医科大学, 医学部, 准教授 (80288703)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | キマーゼ / メタボリックシンドローム / 合併症 / 阻害薬 / 高血圧 / NASH / 脳卒中 / 血管障害 |
|---|
| Research Abstract |
Effects of the chymase inhibitor were evaluated on animal models with the non-alcoholic steatohepatitis (NASH) and stroke-prone spontaneously hypertensive (SHR-SP) rats as complications of the metabolic syndrome. In a hamster NASH model, plasma levels of AST and ALT were improved by the chymase inhibitor and the improvement of lipid deposition and fibrosis was also observed. In SHR-SP rats, the chymase inhibitor showed to prevent the vascular endothelial dysfunction via the anti-oxidative effect and the prevention of inflammatory cell-infiltration into the endothelium without hypotensive effect. The chymase inhibitor also extended the survival term.
These results suggest that chymase inhibition become the useful strategy to prevent the complication of metabolic syndrome.
|
